Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Cancer Res. 2014 Apr 7;74(11):3020–3030. doi: 10.1158/0008-5472.CAN-13-3276

Figure 2. Pharmacologically decreasing prothrombin (fII) expression significantly limits adenoma formation in CAC.

Figure 2

Shown are quantitation of hepatic prothrombin mRNA (A) and chromogenic plasma prothrombin activity (B) obtained following 3 weekly doses of prothrombin-specific ASO (5 mg/kg/dose) or a control oligonucleotide, as well as parallel analyses in unchallenged WT and fII+/− mice (*P < 0.05, n = 4 per group). (C) Weekly treatment with a prothrombin-specific ASO at this dose significantly limits adenoma formation following AOM/DSS challenge relative to a control, irrelevant oligonucleotide.